top of page
The Professional Network for Healthcare Experts
Novartis Phase III HARBOR trial of del-desiran misses primary endpoint in myotonic dystrophy type 1
Novartis reports that the Phase III HARBOR study of del-desiran did not meet its primary endpoint in patients with myotonic dystrophy type 1.
nuaxia
Sep 101 min read
Novartis' Phase III pelacarsen trial misses primary cardiovascular endpoint
Novartis reports that the Phase III Lp(a)HORIZON study of pelacarsen did not meet its primary cardiovascular endpoint in patients with elevated lipoprotein(a) and established cardiovascular disease.
nuaxia
Sep 72 min read
bottom of page